hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Basophil Basophils exhibit large, dark purple granules that often cover the cell's nucleus. They are the rarest of the five normal cell types. Basophilia and eosinophilia can occur along with other white blood cell abnormalities in chronic myeloid leukaemia and other myeloproliferative disorders. An increased basophil count may also be seen in hypersensitivity reactions and after splenectomy. The basophil count may decrease during ovulation, steroid treatment, and periods of physiological stress.
==== Never marketed ==== Alaproclate (GEA-654) Cericlamine (JO-1017) Desmethylcitalopram Didesmethylcitalopram Femoxetine (FG-4963; Malexil) Ifoxetine (CGP-15,210-G) Omiloxetine Panuramine (WY-26,002) Pirandamine (AY-23,713) RTI-353 Seproxetine ((S)-norfluoxetine)
== History == On March 26, 1993, Wang Wei registered SF Express in Shunde, Guangdong. It began operation with six employees with focus on express delivery business between Shunde, Lufeng and Hong Kong. In the late 1990s, SF Holding introduced a performance-based salary system that linked couriers' earnings to the number of parcels delivered and freight costs. In 2002, SF Holding cancelled the franchise system and changed to direct operations. In the same year, it established its headquarters in Futian, Shenzhen. In 2003, the outbreak of SARS led people to avoid shopping in person, accelerating the growth of online shopping and creating a new development opportunity for SF Holding. In the economic depression of that year, SF Holding signed an agreement with Yangtze River Express to charter 5 aircraft. In 2009, SF Holding founded SF Airlines and purchased two cargo planes becoming the only private express delivery company in China that owned its own aircraft. In 2010, SF Holding expanded its business into Singapore, marking its entry into the international market. By 2012, SF Holding air fleet increased to 30 all-cargo charter flights with over 5000 business locations, more than 150 hubs and over 10,000 operating vehicles and reached a turnover of over RMB 20 billion. In 2013, SF Holding expanded its business into new divisions such as cold chain and pharmaceutical logistics, and LTL freight, becoming an integrated logistics service provider.
Sources: en.wikipedia.org
Researchers have hypothesized that the ability of leukocytes to maintain attachment and rolling on the blood vessel wall can be explained by a combination of many factors, including cell flattening to maintain a larger binding surface-area and reduce hydrodynamic drag, as well as tethers holding the rear of the rolling cell to the endothelium breaking and slinging to the front of the rolling cell to reattach to the endothelial wall. These hypotheses work well with Marshall's 2003 findings that selectin bonds go through a catch-slip transition in which initial increases in shear force strengthen the bond, but with enough applied force bond lifetimes begin to decay exponentially. Therefore, the weak binding of a sling at the leading edge of a rolling leukocyte would initially be strengthened as the cell rolls farther and the tension on the bond increases, preventing the cell from dissociating from the endothelial wall and floating freely in the bloodstream despite high shear forces. However, at the trailing edge of the cell, tension becomes high enough to transition the bond from catch to slip, and the bonds tethering the trailing edge eventually break, allowing the cell to roll further instead of remaining stationary.
High-resolution Nuclear Magnetic Resonance. McGraw-Hill Book Company. John D. Roberts (1959). Nuclear Magnetic Resonance: applications to organic chemistry. McGraw-Hill Book Company. ISBN 978-1-258-81166-2. {{cite book}}: ISBN / Date incompatibility (help) Charles P. Slichter (1963). Principles of magnetic resonance: with examples from solid state physics. Harper & Row. ISBN 978-3-540-08476-1. {{cite book}}: ISBN / Date incompatibility (help) J.M. Tyszka; S.E. Fraser; R.E. Jacobs (2005). "Magnetic resonance microscopy: recent advances and applications". Current Opinion in Biotechnology. 16 (1): 93–99. doi:10.1016/j.copbio.2004.11.004. PMID 15722021. Kurt Wüthrich (1986). NMR of Proteins and Nucleic Acids. New York (NY), US: Wiley-Interscience. ISBN 978-0-471-11917-3.
If this arrangement is clockwise, it is assigned an R configuration; if it is counterclockwise, it is assigned an S configuration. In contrast, steroid nomenclature uses α and β to denote stereochemistry at chiral centers. The α and β designations are based on the orientation of substituents relative to each other in a specific ring system. In general, α refers to a substituent that is oriented towards the plane of the ring system, while β refers to a substituent that is oriented away from the plane of the ring system. In steroids drawn from the standard perspective used in this paper, α-bonds are depicted on figures as dashed wedges and β-bonds as solid wedges. The name "11-deoxycortisol" is an example of a derived name that uses cortisol as a parent structure without an oxygen atom (hence "deoxy") attached to position 11 (as a part of a hydroxy group). The numbering of positions of carbon atoms in the steroid nucleus is set in a template found in the Nomenclature of Steroids that is used regardless of whether an atom is present in the steroid in question. Unsaturated carbons (generally, ones that are part of a double bond) in the steroid nucleus are indicated by changing -ane to -ene. This change was traditionally done in the parent name, adding a prefix to denote the position, with or without Δ (Greek capital delta) which designates unsaturation, for example, 4-pregnene-11β,17α-diol-3,20-dione (also Δ4-pregnene-11β,17α-diol-3,20-dione) or 4-androstene-3,11,17-trione (also Δ4-androstene-3,11,17-trione).
The productive output of the Matrix is based upon this repeated cycle of destruction and recreation, to keep the human minds which power it in a stable structure because not every human accepts the simulated reality and if enough of them accumulate, it could cause a catastrophic system crash of the Matrix and subsequent extinction of both humanity and the Machines. The Oracle is as much part of that self-perpetuating design as the Architect and the prophecy of the One is designed to ensure it runs smoothly each time. The Architect warns of the annihilation of all human life in and out of the Matrix if he does not enter the Source door to reload the Matrix, but unlike his predecessors, Neo does not enter the door to the Source; he chooses not to believe the Architect's dire warnings of consequences and to save Trinity instead. Returning to the Matrix, he catches Trinity as she falls from an upper-story window of a power plant. She dies of a gunshot wound to the heart that she sustains during the fall, but Neo brings her back to life by reaching into her virtual body, removing the bullet and restarting her heart. Together, they exit the Matrix and return to the real world. Neo tells Morpheus that the prophecy was merely another system of control and that Zion's destruction is imminent. A group of sentinels begin to converge on their hovercraft, so Neo and the others are forced to abandon it and flee as it is destroyed.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.